SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GUMM - Eliminate the Common Cold
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mad2 who wrote (2897)10/28/2000 6:08:33 PM
From: Mike M  Read Replies (2) of 5582
 
I think you must admit the results with ZICAM have been modest to date delivering little to the bottom line (of GUMM shareholders that is).


I don't have to admit it because I don't believe it. I think they are executing a reasonable business plan and, with a little luck, a number of things will come together in the next six months. The problem with perception is that I look at shareholder value differently than do you. For you it is strictly dollars. I see a company positioned to dramatically increase revenue the next two years.

I also caveat my trust in the efficient market theory. I watched QCOM sit like a bump on a log, price wise, for years as they postured their business for dramatic growth.

The warrants issue is a red herring. To compare with QGLY is preposterous and I used to think you were smart enough to realize that. Maybe you aren't that smart. Not worth arguing about. It will become apparent soon enough...even to you.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News